J&J-linked filings: Phase 2 teclistamab trial in Waldenstrom's, two eye device studies registered

This week brought three newly posted, not-yet-recruiting studies tied to Johnson & Johnson products across oncology and vision care.

• A Massachusetts General Hospital-sponsored Phase 2 trial (NCT07791498) will test teclistamab in relapsed or refractory Waldenstrom's macroglobulinemia, with an open label design enrolling 24 patients who have had one or more prior lines of systemic therapy including an anti-CD20 antibody regimen or a BTK inhibitor.¹ J&J is a collaborator, and the company is supplying the study drug and funding trial activities.¹ The primary outcome is overall IgM response, measured as objective response rate defined as at least 25% improvement in IgM from baseline.¹
• Vance Thompson Vision, with J&J as collaborator, registered a Phase 4 single-arm study (NCT07790887) of bilateral cataract surgery with implantation of the TECNIS PureSee extended depth of focus IOL in subjects with visually significant cataract in a real-world setting.² The study plans to enroll 50 participants² at one U.S. site.
• Johnson & Johnson Vision Care registered a randomized, single-masked trial (NCT07788521) comparing ACUVUE Oasys MAX 1-Day Multifocal (Senofilcon A) against DAILIES AquaComfort Plus Multifocal (Nelfilcon A)³ in presbyopic contact lens wearers. The trial expects to enroll 150 participants³ with a primary completion date of 2026-12-11 (estimated), per the study record.³